Form D · Other Health Care
Mirador Therapeutics, Inc.
San Diego, CA · CIK 0002017193
Offering snapshot reported Apr 3, 2024 · SEC filing
- Reported sold
- $80M Offering amount: $80M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 14, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 3, 2024 | Initial | $80,000,000 | No comparison | 3 | SEC filing |
| Apr 3, 2024 | Initial | $332,999,976 | No comparison | 31 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-509562
Source: Form D, filed Apr 3, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Timothy K. Andrews | Executive |
| Paul Berns | Director |
| David Bonita, M.D. | Director |
| Vika Brough | Executive |
| Kristina Burow | Director |
| Scott Glenn | Director |
| Mark C. Mc Kenna | Director, Executive |
| Joseph Papa | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
3115 Merryfield Row, Suite 210
San Diego, CA, 92121
San Diego, CA, 92121